NasdaqGS - Nasdaq Real Time Price USD

BridgeBio Pharma, Inc. (BBIO)

Compare
25.72 -1.47 (-5.41%)
As of 10:18 AM EST. Market Open.
Loading Chart for BBIO
DELL
  • Previous Close 27.19
  • Open 26.92
  • Bid 25.52 x 100
  • Ask 25.98 x 100
  • Day's Range 25.65 - 27.88
  • 52 Week Range 21.62 - 44.32
  • Volume 945,934
  • Avg. Volume 2,319,395
  • Market Cap (intraday) 4.861B
  • Beta (5Y Monthly) 1.09
  • PE Ratio (TTM) --
  • EPS (TTM) -2.42
  • Earnings Date Feb 20, 2025 - Feb 24, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 48.01

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

bridgebio.com

550

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BBIO

View More

Performance Overview: BBIO

Trailing total returns as of 11/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BBIO
36.29%
S&P 500
25.70%

1-Year Return

BBIO
13.05%
S&P 500
31.51%

3-Year Return

BBIO
36.87%
S&P 500
27.53%

5-Year Return

BBIO
17.14%
S&P 500
91.34%

Compare To: BBIO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BBIO

View More

Valuation Measures

Annual
As of 11/25/2024
  • Market Cap

    5.14B

  • Enterprise Value

    6.60B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    22.77

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    30.32

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -201.53%

  • Return on Assets (ttm)

    -48.88%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    217.76M

  • Net Income Avi to Common (ttm)

    -438.86M

  • Diluted EPS (ttm)

    -2.42

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    266.32M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -365.12M

Research Analysis: BBIO

View More

Company Insights: BBIO

Research Reports: BBIO

View More

People Also Watch